A randomized, open-label, crossover study of once monthly oral Bonviva [ibandronic acid] compared with alendronate [alendronic acid] to determine patient preference in women with post-menopausal osteoporosis

Trial Profile

A randomized, open-label, crossover study of once monthly oral Bonviva [ibandronic acid] compared with alendronate [alendronic acid] to determine patient preference in women with post-menopausal osteoporosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Alendronic acid; Ibandronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 20 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top